Literature DB >> 7076615

The effects of nosocomial infections on the length and costs of hospital stay.

E Rubinstein, M Green, M Modan, P Amit, L Bernstein, A Rubinstein.   

Abstract

Entities:  

Mesh：

Year:  1982        PMID： 7076615     DOI： 10.1093/jac/9.suppl_a.93

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  8 in total

1.  Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability.

Authors:  F Bressolle; J E de la Coussaye; R Ayoub; D Fabre; R Gomeni; G Saissi; J J Eledjam; M Galtier
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 2.  Treatment of urinary tract infection. Clinical and economic considerations.

Authors:  R J Plumridge; C L Golledge
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

3.  Analysis of flexible substrates for clinical translation of laser-generated shockwave therapy.

Authors:  Nathan C Francis; Imara Kassam; Bryan Nowroozi; Warren S Grundfest; Zach D Taylor
Journal:  Biomed Opt Express       Date:  2015-02-17       Impact factor: 3.732

4.  Reduction in surgical wound infection rates associated with reporting data to surgeons.

Authors:  G Taylor; M Buchanan-Chell; T Kirkland; M McKenzie; B Sutherland; R Wiens
Journal:  Can J Infect Dis       Date:  1994-11

5.  Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia.

Authors:  Cassio Girardi; Marc Tonnellier; Ivan Goldstein; Alfonso Sartorius; Frederic Wallet; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2006-07-21       Impact factor: 17.440

6.  Nosocomial infection in surgery wards: a controlled study of increased duration of hospital stays and direct cost of hospitalization.

Authors:  A A Vegas; V M Jodra; M L García
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

7.  Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.

Authors:  A Cometta; J D Baumgartner; D Lew; W Zimmerli; D Pittet; P Chopart; U Schaad; C Herter; P Eggimann; O Huber
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

8.  [Costs due to urinary tract infections in Germany. An estimation based on the data from the German National Nosocomial Infections Surveillance System].

Authors:  R-P Vonberg; M Behnke; H Rüden; P Gastmeier
Journal:  Urologe A       Date:  2008-01       Impact factor: 0.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.